Certain food additives, such as emulsifiers and detergents, have been associated with IBD [1]. The current prospective, observational cohort study (2003-2016) investigated the link between food intake and incident IBD in 116,037 participants from 21 countries [2]. At baseline, habitual food intake was assessed through food frequency questionnaires (FFQ’s). The diagnosis of IBD was determined per self-report. Dr Neeraj Narula (McMaster University, UK) presented the findings of the study.
A multivariate Cox proportional hazard model revealed that the number of processed food servings per day was associated with the occurrence of incident IBD in this cohort. Participants with an intake of ≥5 servings per day had a higher risk of IBD than participants with an intake of <1 serving per day (HR 1.82; P=0.0063). This result was more pronounced in incident Crohn’s disease (HR 4.50) than in incident ulcerative colitis (HR 1.46). The risk of incident IBD was increased for all 4 categories of highly processed food that were analysed in this study: processed meat intake, soft drink intake, the intake of sweets, and salty food and snacks.
- Swidsinski A, et al. Inflamm Bowel Dis 2009;15(3):359-64
- Narula N, et al. Association of Processed Food Intake with Risk of Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) study. OP05, ECCO 2021 Virtual Congress, 2-3 & 8-10 July.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Pausing antiresorptives may not protect cancer patients from jaw osteonecrosis Next Article
Large variability in IBD care and education across Europe »
« Pausing antiresorptives may not protect cancer patients from jaw osteonecrosis Next Article
Large variability in IBD care and education across Europe »
Table of Contents: ECCO 2021
Featured articles
Biologics Updates
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Ustekinumab safe and effective in elderly CD patients
Early clinical remission and response following risankizumab therapy in CD
Risk of hospitalisation and surgery linked to IBD biological
Obesity increases the risk of immunogenicity to adalimumab in IBD
Improvements in Small Molecules
Upadacitinib meets primary endpoint for moderate-to-severe UC
Promising safety and pharmacokinetic data on BT051 for UC
Surgical closure plus anti-TNF outperforms anti-TNF alone for perianal fistula
Novel Biomarkers
Blood proteins predicting relapse in CD identified
Extracellular RNA has potential as a non-invasive biomarker in IBD
Risk Mitigation
No increased risk of (severe) COVID-19 among IBD patients
Oral faecal microbiota transplant therapy efficacious in UC
Artificial intelligence outperforms human classifying of endoscopic images in UC
Increased risk of rectal cancer after colectomy in IBD
Risk of colorectal cancer is detected by low-pass whole genome sequencing
Large variability in IBD care and education across Europe
Ultra-processed food intake associated with IBD
Factors of coping difficulties in IBD revealed
Related Articles
October 9, 2025
TURN2: Well-prepared FMT shows efficacy in UC
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
